RT Journal Article
SR Electronic
T1 PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.28.21250486
DO 10.1101/2021.01.28.21250486
A1 Chantal B.F. Vogels
A1 Mallery I. Breban
A1 Tara Alpert
A1 Mary E. Petrone
A1 Anne E. Watkins
A1 Isabel M. Ott
A1 Jaqueline Goes de Jesus
A1 Ingra Morales Claro
A1 Giulia Magalhães Ferreira
A1 Myuki A.E. Crispim
A1 Brazil-UK CADDE Genomic Network
A1 Lavanya Singh
A1 Houriiyah Tegally
A1 Ugochukwu J. Anyaneji
A1 NGS-SA
A1 Emma B. Hodcroft
A1 Christopher E. Mason
A1 Gaurav Khullar
A1 Jessica Metti
A1 Joel T. Dudley
A1 Matthew J. MacKay
A1 Megan Nash
A1 Jianhui Wang
A1 Chen Liu
A1 Pei Hui
A1 Steven Murphy
A1 Caleb Neal
A1 Eva Laszlo
A1 Marie L. Landry
A1 Anthony Muyombwe
A1 Randy Downing
A1 Jafar Razeq
A1 Tulio de Oliveira
A1 Nuno R. Faria
A1 Ester C. Sabino
A1 Richard A. Neher
A1 Joseph R. Fauver
A1 Nathan D. Grubaugh
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.01.28.21250486.abstract
AB With the emergence of SARS-CoV-2 variants that may increase transmissibility and/or cause escape from immune responses1–3, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant first detected in the UK4,5 could be serendipitously detected by the ThermoFisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a “spike gene target failure” (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike Δ69-70, such as B.1.351 (also 501Y.V2) detected in South Africa6 and P.1 (also 501Y.V3) recently detected in Brazil7. We identified a deletion in the ORF1a gene (ORF1a Δ3675-3677) in all three variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a Δ3675-3677 as the primary target and spike Δ69-70 to differentiate, we designed and validated an open source PCR assay to detect SARS-CoV-2 variants of concern8. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence spread of B.1.1.7, B.1.351, and P.1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by CTSA Grant Number TL1 TR001864 (TA and MEP), Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z), a Medical Research Council-Sao Paulo Research Foundation CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (NDG), and CDC Contract # 75D30120C09570 (NDG). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:United States: The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599). Brazil: Sample collection and genetic characterization was approved under the Brazilian National IRB (CONEP) CAAE 30101720.1.0000.0068. South Africa: We used de-identified remnant nasopharyngeal and oropharyngeal swab samples from patients testing positive for SARS-CoV-2 by RT-qPCR from public health and private medical diagnostics laboratories in South Africa. The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee (protocol reference no. BREC/00001195/2020; project title: COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: epidemiological investigation to guide prevention and clinical care). Individual participant consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees. The sample IDs displayed in Source Data Fig 2 are not known outside the research groups and cannot be used to re-identify any subject. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data are available on GISAID (see Source Data Fig 2 for accession numbers). All RT-qPCR data are included in this article, supplementary files, and source data. https://www.gisaid.org/